Oncotarget

Research Papers:

Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma

De-jun Yang, Kun-lun Luo, Hong Liu, Bing Cai, Guo-qing Tao, Xiao-fang Su, Xiao-juan Hou, Fei Ye, Xiang-yong Li and Zhi-qiang Tian _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:2960-2970. https://doi.org/10.18632/oncotarget.13813

Metrics: PDF 2089 views  |   HTML 2550 views  |   ?  


Abstract

De-jun Yang1,*, Kun-lun Luo3,*, Hong Liu3,*, Bing Cai2, Guo-qing Tao2, Xiao-fang Su3, Xiao-juan Hou4, Fei Ye4, Xiang-yong Li3, Zhi-qiang Tian2,3,4

1Department of Gastrointestinal Surgery, The Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China

2Department of General Surgery, Wuxi People's Hospital Affiliated Nanjing Medical University, Wuxi 214023, China

3Department of General Surgery and Rehabilitation Medicine and Oncology, The 101st Hospital of Chinese PLA, Wuxi 214044, China

4Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200438, China

*These authors contributed equally to this work

Correspondence to:

Zhi-qiang Tian, email: [email protected]

Xiang-yong Li, email: [email protected]

Keywords: transcatheter arterial chemoembolization, radiofrequency ablation, hepatocellular carcinoma, meta-analysis

Received: June 11, 2016     Accepted: November 30, 2016     Published: December 07, 2016

ABSTRACT

This meta-analysis was conducted to compare transcatheter arterial chemoembolization (TACE) plus radiofrequency ablation (RFA) with TACE alone for hepatocellular carcinoma. We searched MEDLINE, EMBASE and CENTRAL for all relative randomized controlled trials (RCTs) and retrospective studies until October 31 2016. Tumor response, recurrence-free survival, overall survival and postoperative complications were the major evaluation indices. Review Manager (version 5.3) was used to analyze the data. Dichotomous data was calculated by odds ratio (OR) with 95% confidence intervals (CI). There were 1 RCT and 10 retrospective studies with 928 patients in this meta-analysis: 412 patients with TACE plus RFA and 516 patients with TACE alone. Compared with TACE alone group, TACE plus RFA group attained higher tumor response rates (OR = 6.08, 95% CI = 4.00 to 9.26, P < 0.00001), achieved longer recurrence-free survival rates (ORRFS = 3.78, 95% CI: 2.38 to 6.02, P < 0.00001) and overall survival rates (OR1-year = 3.92, 95% CI = 2.41–6.39, P < 0.00001; OR3-year = 2.56; 95% CI = 1.81–3.60; P < 0.00001; OR5-year = 2.78; 95% CI = 1.77–4.38; P < 0.0001). Serious postoperative complications were not observed, although complications were higher in TACE plus RFA group than that in TACE alone group (OR = 2.74, 95% CI = 1.07 to 7.07, P = 0.04). In conclusion, the use of TACE plus RFA for intermediate stage hepatocellular carcinoma can attain higher tumor response rates and improve survival rates than TACE alone.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13813